DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs

Cell. 2023 Jun 22;186(13):2765-2782.e28. doi: 10.1016/j.cell.2023.05.028. Epub 2023 Jun 15.


Cancer is characterized by hypomethylation-associated silencing of large chromatin domains, whose contribution to tumorigenesis is uncertain. Through high-resolution genome-wide single-cell DNA methylation sequencing, we identify 40 core domains that are uniformly hypomethylated from the earliest detectable stages of prostate malignancy through metastatic circulating tumor cells (CTCs). Nested among these repressive domains are smaller loci with preserved methylation that escape silencing and are enriched for cell proliferation genes. Transcriptionally silenced genes within the core hypomethylated domains are enriched for immune-related genes; prominent among these is a single gene cluster harboring all five CD1 genes that present lipid antigens to NKT cells and four IFI16-related interferon-inducible genes implicated in innate immunity. The re-expression of CD1 or IFI16 murine orthologs in immuno-competent mice abrogates tumorigenesis, accompanied by the activation of anti-tumor immunity. Thus, early epigenetic changes may shape tumorigenesis, targeting co-located genes within defined chromosomal loci. Hypomethylation domains are detectable in blood specimens enriched for CTCs.

Keywords: CD1A; DNA hypomethylation; IFI16; NKT cells; circulating tumor cells; immune surveillance; lipid antigens; prostate cancer; single-cell sequencing; tumorigenesis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinogenesis / genetics
  • DNA
  • DNA Methylation*
  • Epigenesis, Genetic
  • Humans
  • Male
  • Mice
  • Neoplastic Cells, Circulating
  • Prostatic Neoplasms* / genetics


  • DNA